Month: September 2026

Sampo plc, press release, 22 September 2026 at 9:20 am EEST

NOT FOR DISTRIBUTION INTO THE UNITED STATES

Sampo has reduced its ownership in NOBA

Sampo plc (“Sampo”) has sold approximately 14.7 million shares in NOBA Bank Group AB (publ), (“NOBA” or the “Company”) to institutional investors in an accelerated bookbuilding process (“Share Sale”).

The Share Sale generated approximately EUR 111 million in gross proceeds for Sampo. After the Share Sale, Sampo holds around 50.1 million NOBA shares, corresponding to an ownership of 10.01 per cent of the Company.

DNB Carnegie, Goldman Sachs Bank Europe SE and J.P. Morgan SE acted as Managers on the accelerated bookbuilding process.

Nordic Capital coordinated with Sampo in the process but decided not to sell any shares at this point in time. Sampo and Nordic Capital have undertaken to the Managers not to transfer or dispose of any of its remaining holding of shares in NOBA for 45 days after the settlement of the Share Sale, subject to certain customary exceptions and waiver by the Managers.

For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
The principal media
www.sampo.com  

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 22 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares	21 September 2026
Number of Shares purchased	35,658 Class A Shares
Highest price/lowest price paid	£14.54 / £14.50
ISIN for the Shares	GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,904,047‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,904,047 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of Neuberger Private Equity Partners. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. Neuberger Private Equity Partners seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

From: CoinShares XBT Provider AB (publ) (the “Issuer”)
Artillerigatan 6,
114 51 Stockholm,
Sweden

To:         The Security Holders (as defined below)

Cc:         The Law Debenture Trust Corporation p.l.c. (the “Trustee”)
        8^th Floor
        100 Bishopsgate
        London EC2N 4AG
        Attention: the Manager, Commercial Trusts (TC:205928)
        

22 September 2026

IMPORTANT NOTICE TO SECURITY HOLDERS

Re: Compulsory Redemption of Digital Securities issued under the Digital Securities programme of the Issuer

We refer to the base prospectus dated 12 March 2026, relating to the Issuer’s Exchange Traded Products Programme for the issuance of Digital Securities (the “Programme”). We also refer to the trust instrument between the Issuer and the Trustee dated 25 April 2025 as amended and supplemented by the supplemental trust instrument dated 12 March 2026 (the “Trust Instrument”). Capitalised terms used and not defined herein shall have the meanings given to them in the Trust Instrument.

1. Redemption of relevant Digital Securities

In accordance with Condition 10.1(a) (Compulsory Redemption on Termination) of the Digital Securities, the Issuer hereby gives Security Holders not less than 30 days’ notice that it has determined that all Digital Securities issued under the Programme are to be Redeemed compulsorily (the “Redemption”). The relevant Digital Securities are listed in the table below. As used herein, “Security Holders” means the holders of such Digital Securities.

Name	Ticker	Launch date	ISIN
CoinShares XBT Physical Litecoin – SEK	COINLTC SS	21 May 2025	SE0024367098
CoinShares XBT Physical XRP – SEK	COINXRP SS	21 May 2025	SE0024367130
CoinShares XBT Physical Chainlink – SEK	COINLINK SS	21 May 2025	SE0024367080
CoinShares XBT Physical Uniswap – SEK	COINUNI SS	21 May 2025	SE0024367122
CoinShares XBT Physical Staked Cardano – SEK	COINADA SS	21 May 2025	SE0024367106
CoinShares XBT Physical Staked Solana – SEK	COINSOL SS	21 May 2025	SE0024367114
CoinShares XBT Physical Staked Polkadot – SEK	COINDOT SS	21 May 2025	SE0025010838

For the avoidance of doubt, nothing in this notice shall affect the Single Digital Currency Tracker Certificates or Basket Certificates (namely, CoinShares XBT Bitcoin Tracker One (ISIN: SE0007126024), CoinShares XBT Bitcoin Tracker Euro (ISIN: SE0007525332), CoinShares XBT Ether Tracker One (ISIN: SE0010296574) and CoinShares XBT Ether Tracker Euro (ISIN: SE0010296582)), issued by the Issuer pursuant to the base prospectus dated 17 September 2026, as guaranteed by CoinShares Capital Markets (Jersey) Limited.

1. Rationale for the Redemption

The Programme was launched in April 2025 as a Nordic counterpart to the wider European physically-backed exchange-traded product platform operated by the CoinShares group of companies, of which the Issuer is a member (the “Group“). The Programme was constructed deliberately around the same underlying assets and the same physically backed methodology, listed on Nasdaq Stockholm and denominated in Swedish krona, for Nordic investors who prefer to trade in their home currency on their home exchange and with a local issuer.

The Group has since decided to concentrate its altcoin and staking exposure on a single platform and will continue exploring the most efficient ways to offer altcoin and staking exposures to Nordic investors going forward. Following that decision, the Issuer has determined that it is appropriate to redeem all outstanding Digital Securities issued under the Programme and to terminate the Programme accordingly.

1. Compulsory Redemption Date

The Issuer hereby designates 9 November 2026 as the Compulsory Redemption Date in respect of the Redemption of all of the Digital Securities under the Programme.

1. Redemption election

The Issuer reminds Security Holders that Redemption pursuant to Condition 10.1 in respect of any Digital Security will be effected by Cash Settlement in accordance with Condition 10.8 (Payments of Cash on Compulsory Redemption) unless the Security Holder in respect of the Digital Security has, no later than 26 October 2026 (being ten Issuer Business Days prior to the Compulsory Redemption Date), delivered to the Issuer a valid Redemption Notice specifying Physical Delivery and effected an Acceptable Delivery in respect of the Digital Securities to be Redeemed. Where Redemption pursuant to Condition 10.1 in respect of any Digital Security is to be effected by Physical Delivery, Condition 10.7 (Delivery of Digital Currency on Compulsory Redemption) will apply. Redemption Notices specifying Physical Delivery should be sent to ir@xbtprovider.com.

1. Redemption procedure

Subject to the above, settlement of the Issuer’s Redemption Obligations on Redemption pursuant to Condition 10.1 shall be effected on the Compulsory Redemption Date or such later date as soon thereafter as reasonably practicable and in any event by 30 November 2026 (being the fifteenth Issuer Business Day after the Compulsory Redemption Date). The Compulsory Redemption Date or the aforementioned later date is referred to herein as the “Compulsory Redemption Settlement Date”.

Where the Redemption is being effected by Cash Settlement:

(i)     The Issuer will, in accordance with Condition 10.8 (Payments of Cash on Compulsory Redemption), transfer the aggregate Redemption Amount with respect to the Digital Securities in the Settlement Currency (being Swedish Krona) on the Compulsory Redemption Settlement Date, or, if such date is not a Clearing System Business Day, on the immediately following Clearing System Business Day, to the relevant Security Holder in accordance with Condition 29 (Payment Provisions).

(ii)     The Redemption Amount will be an amount in the Settlement Currency equal to the net proceeds of sale (and conversion into the Settlement Currency if not sold for cash in the Settlement Currency) of the aggregate Coin Entitlement in Digital Currency of the relevant Underlying Type of such Digital Securities rounded down to the Delivery Precision Level of such Digital Securities as at the date on which settlement of such sale was completed less the Redemption Fee and any other Redemption Deductions.

(iii)     The Redemption Fee in relation to the Redemption shall be nil. Redemption Deductions include the costs, charges and/or fees incurred by the Issuer in connection with the Redemption, as more fully set out in the definition thereof in the Conditions.

Where the Redemption is being effected by Physical Delivery:

(i)     The Issuer will, in accordance with Condition 10.7 (Delivery of Digital Currency on Compulsory Redemption), instruct the Custodian to transfer Digital Currency of the Underlying Type attributable to or forming part of the Secured Property in respect of such Digital Securities, in an amount (rounded down to the Delivery Precision Level) equal to the Redemption Amount, calculated as at the Compulsory Redemption Settlement Date, to the relevant Security Holder Account. Such Digital Currency will be delivered to such account on the Compulsory Redemption Settlement Date.

(ii)     The Redemption Amount will be the aggregate Coin Entitlement in Digital Currency of the relevant Underlying Type of such Digital Securities as at the Settlement Date rounded down to the Delivery Precision Level less an amount of such Digital Currency having a value equal (in the opinion of the Determination Agent) to the Redemption Fee and any other Redemption Deductions rounded up to the Delivery Precision Level.

(iii)     The Redemption Fee in relation to the Redemption shall be nil. Redemption Deductions include the costs, charges and/or fees incurred by the Issuer in connection with the Redemption as more fully set out in the definition thereof in the Conditions and which will include, without limitation, any costs incurred by the Issuer, the Custodian(s), the Coin Sales Agent or any other of the Issuer’s agents as part of a sale or purchase of Digital Currency. In this context, a Physical Delivery Fee of one (1) per cent. of the applicable Coin Entitlement will be charged under limb (a) of the definition of Redemption Deductions.

The provisions and procedures described above are qualified entirely by, and subject to, the more detailed terms and definitions set out in the Conditions relating to the Digital Securities.

1. Other

This notice of Compulsory Redemption is governed by English law and is given by CoinShares XBT Provider AB (publ) as Issuer. The Issuer approved the Redemption of Digital Securities by resolutions dated 25 August 2026.

For further information, please contact: ir@xbtprovider.com.

CoinShares XBT Provider AB (publ)

DISCLAIMER: This notice of Compulsory Redemption contains important information which should be read carefully. If any Security Holder is in any doubt as to the action it should take, it is recommended to seek their own financial and legal advice.

Nothing in this notice of Compulsory Redemption constitutes or contemplates an offer of, an offer to purchase or the solicitation of an offer to sell any security in any jurisdiction and participation by a Security Holder in any circumstances in which such participation is unlawful will not be accepted.

The distribution of this notice of Compulsory Redemption in certain jurisdictions may be restricted by law. Persons into whose possession this notice of Compulsory Redemption comes are required by the Issuer to inform themselves about, and to observe, any such restrictions.

Från: CoinShares XBT Provider AB (publ) (”Emittenten”, eng. the Issuer)
Artillerigatan 6,
114 51 Stockholm, Sverige

Till:         Värdepappersinnehavarna (enligt definitionen nedan)

Kopia: The Law Debenture Trust Corporation p.l.c. (”Trusteen”, eng. the Trustee)
        8^th Floor
        100 Bishopsgate
        London EC2N 4AG
        Att: Trustee, Commercial Trusts (TC:205928)
        

22 september 2026

VIKTIGT MEDDELANDE TILL VÄRDEPAPPERSINNEHAVARE

Angående: Obligatorisk Inlösen (eng. Compulsory Redemption) av Digitala Värdepapper (eng. Digital Securities) utgivna inom ramen för Emittentens program för Digitala Värdepapper

Vi hänvisar till grundprospektet daterat den 12 mars 2026, avseende Emittentens Program för Börshandlade Produkter (eng. Exchange Traded Products Programme) för emission av Digitala Värdepapper (”Programmet”, Eng. the Programme). Vi hänvisar även till trusteeavtalet (eng. Trust Instrument) mellan Emittenten och Trusteen daterat den 25 april 2025, i dess lydelse enligt tillägg och ändringar i det kompletterande trusteeavtalet daterat den 12 mars 2026 (”Trusteeavtalet”). Termer som skrivs med versaler och som inte definieras här ska ha den betydelse som anges i Trusteeavtalet.

1.         Inlösen av berörda digitala värdepapper

I enlighet med Villkor 10.1(a) (Obligatorisk Inlösen vid Upphörande, eng. Compulsory Redemption on Termination) för de Digitala Värdepapperen meddelar Emittenten härmed Värdepappersinnehavarna (eng. Securityholders) med minst 30 dagars varsel att Emittenten har beslutat att alla Digitala Värdepapper som emitterats inom ramen för programmet ska lösas in obligatoriskt (”Inlösen”, eng. Redemption). De berörda Digitala Värdepapperen anges i tabellen nedan. I detta dokument avses med ”Värdepappersinnehavare” innehavarna av sådana Digitala Värdepapper.

Namn	Ticker	Lanseringsda tum	ISIN
CoinShares XBT Physical Litecoin – SEK	COINLTC SS	21 maj 2025	SE0024367098
CoinShares XBT Physical XRP – SEK	COINXRP SS	21 maj 2025	SE0024367130
CoinShares XBT Physical Chainlink – SEK	COINLINK SS	21 maj 2025	SE0024367080
CoinShares XBT Physical Uniswap – SEK	COINUNI SS	21 maj 2025	SE0024367122
CoinShares XBT Physical Staked Cardano – SEK	COINADA SS	21 maj 2025	SE0024367106
CoinShares XBT Physical Staked Solana – SEK	COINSOL SS	21 maj 2025	SE0024367114
CoinShares XBT Physical Staked Polkadot – SEK	COINDOT SS	21 maj 2025	SE0025010838

För att undvika tvivel ska inget i detta meddelande påverka Certifikaten för Enskilda Digitala Valutor (eng. Single Digital Currency Tracker Certificates) eller Korgcertifikaten (eng. Basket Certificates) (nämligen CoinShares XBT Bitcoin Tracker One (ISIN: SE0007126024), CoinShares XBT Bitcoin Tracker Euro (ISIN: SE0007525332), CoinShares XBT Ether Tracker One (ISIN: SE0010296574) och CoinShares XBT Ether Tracker Euro (ISIN: SE0010296582)), utgivna av Emittenten i enlighet med grundprospektet daterat den 17 september 2026, med garanti från CoinShares Capital Markets (Jersey) Limited.

2.         Motivering till Inlösen

Programmet lanserades i april 2025 som en nordisk motsvarighet till den bredare europeiska plattformen för fysiskt backade börshandlade produkter som drivs av CoinShares-koncernen, där Emittenten ingår (”Koncernen”, eng. the Group). Programmet utformades medvetet kring samma underliggande tillgångar och samma metod för fysisk backning, noterat på Nasdaq Stockholm och denominerat i svenska kronor, för nordiska investerare som föredrar att handla i sin hemvaluta på sin hembörs och med en lokal emittent.

Koncernen har sedan dess beslutat att koncentrera sin exponering mot altcoins och staking till en enda plattform och kommer även framöver att fortsätta utforska de mest effektiva sätten att erbjuda nordiska investerare exponering mot altcoins och staking. Till följd av detta beslut har Emittenten beslutat att det är lämpligt att lösa in alla utestående Digitala Värdepapper som emitterats inom ramen för Programmet och att därmed avsluta Programmet.

3.         Datum för obligatorisk inlösen

Emittenten fastställer härmed den 9 november 2026 som datum för Obligatorisk Inlösen avseende Inlösen av alla Digitala Värdepapper inom ramen för Programmet.

4.         Val av Inlösen

Emittenten påminner Värdepappersinnehavarna om att Inlösen enligt villkor 10.1 avseende ett Digitalt Värdepapper kommer att ske genom Kontantavräkning (eng. Cash Settlement) i enlighet med villkor 10.8 (Kontantbetalningar vid Obligatorisk Inlösen, eng. Payments of Cash on Compulsory Redemption), såvida inte Värdepappersinnehavaren avseende det Digitala Värdepapperet senast 26 oktober 2026 (vilket motsvarar tio Emittentbankdagar (eng. Issuer Business Days) före den Obligatoriska Inlösendagen (eng. Compulsory Redemption Date)), har lämnat in en giltig Inlösenanmälan (eng. Redemption Notice) till Emittenten där Fysisk Leverans (eng. Physical Delivery) anges och genomfört en godtagbar leverans avseende de Digitala Värdepapper som ska lösas in. Om Inlösen enligt villkor 10.1 avseende ett Digitalt Värdepapper ska ske genom fysisk leverans, gäller villkor 10.7 (Leverans av Digital Valuta vid Obligatorisk Inlösen). Inlösenanmälan där Fysisk Leverans anges ska skickas till ir@xbtprovider.com.

5.         Inlösenförfarande

Med förbehåll för ovanstående ska avvecklingen av Emittentens Inlösenförpliktelser (eng. Redemption Obligations) vid Inlösen enligt villkor 10.1 ske på den Obligatoriska Inlösendagen eller ett senare datum så snart därefter som det är rimligt möjligt och under alla omständigheter senast den 30 november 2026 (vilket är den femtonde Emittentbankdagen efter den Obligatoriska Inlösendagen). Den Obligatoriska Inlösendagen eller det ovannämnda senare datumet benämns här ”Avvecklingsdagen för Obligatorisk Inlösen” (eng. Compulosry Redemption Settlement Date).

Om Inlösen sker genom Kontantavräkning:

(i)     Emittenten ska, i enlighet med villkor 10.8 (Kontantbetalningar vid Obligatorisk Inlösen, eng. Payments of Cahs on Compulsory Redemption), överföra det sammanlagda Inlösenbeloppet (eng. Redemption Amount) avseende de Digitala Värdepapperen i Avvecklingsvalutan (eng. Settlement Currency) (d.v.s. svenska kronor) på Avvecklingsdagen för Obligatorisk Inlösen, eller, om detta datum inte är en Bankdag i Clearingsystemet (eng. Clearing System Business Day), på den omedelbart efterföljande Bankdagen i Clearingsystemet, till den berörda Värdepappersinnehavaren i enlighet med villkor 29 (Betalningsbestämmelser).

(ii)     Inlösenbeloppet ska utgöras av ett belopp i Avvecklingsvalutan som motsvarar nettointäkterna från försäljningen (och omräkningen till Avvecklingsvalutan om försäljningen inte skett mot kontanter i Avvecklingsvalutan) av den sammanlagda Mynträttigheten (eng. Coin Entitlement) i Digital Valuta av den relevanta Underliggande Typen (eng. Underlying Type) för sådana Digitala Värdepapper, avrundat nedåt till Leveransprecisionsnivån (eng. Delivery Precision Level) för sådana Digitala Värdepapper per den dag då avvecklingen av sådan försäljning slutfördes, med avdrag för Inlösenavgiften (eng. Redemption Fee) och eventuella övriga Inlösenavdrag (eng.

Redemption Deductions).

(iii)     Inlösenavgiften i samband med Inlösen ska vara noll. Inlösenavdrag omfattar de kostnader, avgifter och/eller arvoden som Emittenten ådrar sig i samband med inlösen, vilket beskrivs närmare i definitionen av detta begrepp i villkoren.

Om Inlösen sker genom Fysisk Leverans:

(i)     Emittenten ska, i enlighet med villkor 10.7 (Leverans av Digital Valuta vid Obligatorisk Inlösen, eng. Delivery of Digital Currency on Compulsory Redemption), ge Förvaringsinstitutet (eng. Custodian) i uppdrag att överföra Digital Valuta av den

Underliggande Typen som kan hänföras till eller utgör en del av den Pantsatta Egendomen (eng. Secured Property) avseende sådana Digitala Värdepapper, till ett belopp (avrundat nedåt till Leveransprecisionsnivån) som motsvarar Inlösenbeloppet, beräknat per Avvecklingsdagen för Obligatorisk Inlösen, till det berörda Värdepappersinnehavarkontot (eng. Security Holder Account). Sådan Digital Valuta kommer att levereras till det kontot på Avvecklingsdagen för Obligatorisk Inlösen.

(ii)     Inlösenbeloppet ska utgöras av den sammanlagda Mynträttigheten i Digital Valuta av den relevanta Underliggande Typen för sådana Digitala Värdepapper per Avvecklingsdagen, avrundat nedåt till Leveransprecisionsnivån, med avdrag för ett belopp av sådan Digital Valuta vars värde (enligt Fastställelseagentens (eng. Determination Agent) bedömning) motsvarar Inlösenavgiften och eventuella andra Inlösenavdrag, avrundat uppåt till Leveransprecisionsnivån.

(iii)     Inlösenavgiften i samband med Inlösen ska vara noll. Inlösenavdrag omfattar de kostnader, avgifter och/eller arvoden som Emittenten ådrar sig i samband med Inlösen, såsom närmare anges i definitionen av dessa i Villkor, och som utan begränsning ska omfatta alla kostnader som Emittenten, Förvaringsinstitut, Myntförsäljningsagenten (eng. Coin Sales Agent) eller någon annan av Emittentens ombud ådrar sig som en del av en försäljning eller ett köp av Digital Valuta. I detta sammanhang kommer en Avgift för Fysisk Leverans på en (1) procent av den tillämpliga Mynträttigheten att debiteras enligt punkt (a) i definitionen av Inlösenavdrag.

De bestämmelser och förfaranden som beskrivs ovan regleras helt och hållet av, och är underordnade, de mer detaljerade villkoren och definitionerna som anges i Villkoren avseende de Digitala Värdepapperen.

6.         Övrigt

Detta meddelande om Obligatorisk Inlösen regleras av engelsk lag och utfärdas av CoinShares XBT Provider AB (publ) i egenskap av Emittent. Emittenten godkände Inlösen av Digitala Värdepapper genom beslut daterat den 25 augusti 2026.

För ytterligare information, vänligen kontakta: ir@xbtprovider.com.

CoinShares XBT Provider AB (publ)

ANSVARSFRISKRIVNING: Detta meddelande om Obligatorisk Inlösen innehåller viktig information som bör läsas noggrant. Om en Värdepappersinnehavare är osäker på vilka åtgärder som bör vidtas rekommenderas det att denne söker egen finansiell och juridisk rådgivning.

Ingenting i detta meddelande om Obligatorisk Inlösen utgör eller avser ett erbjudande om, ett erbjudande att köpa eller en uppmaning till ett erbjudande om att sälja något värdepapper i någon jurisdiktion, och deltagande av en Värdepappersinnehavare under omständigheter där sådant deltagande är olagligt kommer inte att accepteras.

Spridningen av detta meddelande om Obligatorisk Inlösen kan vara begränsad enligt lag i vissa jurisdiktioner. Emittenten kräver att personer som kommer i besittning av detta meddelande om Obligatorisk Inlösen informerar sig om och iakttar sådana begränsningar.

Singapore focuses on infrastructure readiness, Australia advances on AI returns, Japan prioritizes compliance, and South Korea highlights interconnection as markets take different paths to value

SINGAPORE, Sept. 22, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, recently released its 2026 Global Data Insights Survey (GDIS), showing strong AI investment momentum across the region alongside significant differences in how individual markets are turning that investment into business value.

Based on the Asia Pacific (APAC) findings, nearly six in ten (59%) of the region’s respondents expect their organizations to increase AI investment by more than 25% in 2026 compared with 2025, versus 55% globally. More than one-third (36%) have already identified repeatable, high-impact AI use cases, while a similar proportion reports measurable business outcomes from AI.

Beneath the regional picture, the findings show that enterprises are progressing at different stages and prioritizing different requirements as they move AI into wider deployment.

APAC markets are taking different routes from AI investment to value
In Australia, enterprises appear further along in converting AI deployment into financial returns. One-third (33%) of organizations say they are currently realizing AI ROI, more than double the APAC average of 16%. Nearly half (47%) also have real-time AI in deployment, compared with 36% across the region.

In Japan, compliance features prominently in how respondents assess AI strategy and infrastructure decisions. 30% of respondents rank ensuring compliance with AI and data privacy regulations as the top requirement for a successful AI strategy, compared with 18% across APAC. When deciding where to host AI workloads, 22% rank regulatory compliance as their top consideration, compared with 12% regionally.

In Singapore, infrastructure readiness is becoming an important consideration as enterprises advance their AI plans. Half (50%) of respondents cite a lack of specialized AI infrastructure as a challenge, compared with 40% across APAC, while 39% are already reporting measurable business outcomes from AI.

In South Korea, enterprises emphasize connecting distributed data sources to support AI execution. Nearly a quarter (24%) of respondents rank reliable interconnection first among requirements for AI strategy success, compared with 14% across APAC. Almost half (46%) report integrated interconnection across key cloud and infrastructure platforms or architecture centered on dynamic, on-demand interconnection.

“AI investment is accelerating across APAC, and enterprises are entering the next phase with different priorities. As they scale AI, organizations are balancing priorities that range from demonstrating returns and preparing infrastructure to meeting compliance requirements and connecting distributed environments,” said Serene Nah, Managing Director and Head of APAC at Digital Realty.

“These differences matter for enterprises operating across the region. Infrastructure decisions need to reflect the requirements of each market and workload, while giving organizations the flexibility to connect and grow across APAC.”

Different AI paths are shaping infrastructure decisions
As enterprises put more investment behind AI, the survey indicates that decisions around infrastructure and data location are becoming more closely tied to how AI is deployed.

Across APAC, 92% of respondents tie their data-location strategy to their AI plans. At the same time, 88% already follow a distributed data approach, meaning enterprise data, applications and workloads increasingly sit across multiple locations and environments.

Connecting those environments remains a challenge. Only 22% of APAC respondents describe their hybrid infrastructure as fully integrated, even as enterprises increasingly need to bring together data, compute, clouds and partners across markets.

This creates a more complex infrastructure requirement for organizations operating regionally. The location of AI workloads needs to account for factors such as infrastructure availability, performance and local operating requirements, while remaining connected to the wider enterprise architecture.

As AI moves further into production, enterprises will need to make increasingly deliberate choices about where workloads and data reside and how those environments connect. The priority is giving organizations the flexibility to deploy according to local requirements without creating disconnected infrastructure across the region. Through PlatformDIGITAL^®, Digital Realty provides AI-ready infrastructure and connectivity across markets, helping customers bring together the data, applications, clouds and ecosystems they need as their AI strategies evolve.

The research surveyed 2,131 IT decision-makers across 19 countries, including 707 respondents across seven APAC markets: Australia, Hong Kong, India, Indonesia, Japan, Singapore and South Korea.

The full report is available at Global Data Insights Survey 2026.

Methodology
The 2026 Global Data Insights Survey surveyed 2,131 IT decision-makers across 19 countries and eleven industries, including financial services, manufacturing, wholesale and retail trade, healthcare and pharmaceuticals, travel, transportation and logistics, business and professional services, energy and utilities, and media and entertainment. Respondents represented organizations with between 500 and more than 10,000 employees.

About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

For Additional Information

Media Contacts
Joyce Ng
Digital Realty
jong@digitalrealty.com

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

Safe Harbor Statement
This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the APAC market, emerging technologies including AI, expected growth in digital transformation, adoption of AI infrastructure, company strategy and capabilities and customer demand. For a list and description of such risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Please see below information about transactions made under the third tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 22 July 2026.

The duration of the buy-back tranche: 23 July to no later than 26 October 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 22 July 2026, available here: https://newsweb.oslobors.no/message/678529

From 14 September to 18 September 2026, Equinor ASA has purchased a total of 535,701 own shares at an average price of NOK 419.4578 per share.

Overview of transactions:

Date	Trading venue	Aggregated daily volume (number of shares)	Daily weighted average share price (NOK)	Total daily transaction value (NOK)
14 September	OSE	132,000	422.0259	55,707,418.80
	CEUX
	TQEX
15 September	OSE
	CEUX
	TQEX
16 September	OSE	134,000	423.8777	56,799,611.80
	CEUX
	TQEX
17 September	OSE	133,701	416.6691	55,709,075.34
	CEUX
	TQEX
18 September	OSE	136,000	415.3517	56,487,831.20
	CEUX
	TQEX
Total for the period	OSE	535,701	419.4578	224,703,937.14
	CEUX
	TQEX
Previously disclosed buy-backs under the tranche	OSE	5,032,090	390.6069	1,965,568,991.57
	CEUX
	TQEX
	Total	5,032,090	390.6069	1,965,568,991.57
Total buy-backs under the tranche (accumulated)	OSE	5,567,791	393.3827	2,190,272,928.71
	CEUX
	TQEX
	Total	5,567,791	393.3827	2,190,272,928.71

Following completion of the above transactions, Equinor ASA owns a total of 20,202,526 own shares, corresponding to 0.85% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 9,102,766 own shares, corresponding to 0.38% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Attachment

• Detailed overview of transactions

Vitry-le-François, France – September 22, 2026, 8:00 am (CEST)

Haffner Energy launches SB-HEFA (Solid Biomass to HEFA), an innovative process for producing renewable diesel and SAF based on its proprietary thermolysis technology, which directly converts solid biomass into liquid without going through syngas. With feedstock available at less than 20% of the cost of the oils used in HEFA/HVO pathways, together with a very short industrial process chain and improved energy efficiency, Haffner Energy is targeting an approximately 50% reduction in the levelised cost of production (LCOE). SB-HEFA is thus reshaping the economics of the SAF and renewable diesel markets.

Haffner Energy’s thermolysis technology already generates oil, which is immediately converted into non-condensable gases in the process used to produce syngas, hydrogen, methane or methanol. The SB-HEFA process eliminates the reforming step used to convert the oil into gas. Instead, the thermolysis oil is extracted and stabilised through immediate cooling, before undergoing filtration followed by hydrodeoxygenation using proven technologies from the HEFA industry.

“The strength of SB-HEFA lies in combining our existing core technology with a simple, already industrialised conversion chain. By radically transforming the economics of renewable diesel and SAF, SB-HEFA creates the conditions for their large-scale deployment. This represents a paradigm shift for both markets,” said Philippe Haffner, Chairman and Chief Executive Officer of Haffner Energy.

Several major players in the aviation ecosystem have already entered into discussions with Haffner Energy regarding SB-HEFA.

Renewable diesel, which relies on the same technology, is notably one of the key pillars of the Multi-Energy Hubs being developed in Canada with Mundi Énergies.

A radically different economic equation

Feedstock is by far the largest cost component in the production of HEFA fuels (SAF and renewable diesel). In 2026, used cooking oil (UCO) trades in Europe at around €1,000 to €1,200 per tonne¹, equivalent to €100 to €120/MWh of primary energy. By contrast, the residual solid biomass used to feed SB-HEFA is typically available at between €10 and €30/MWh, representing a cost that is, on average, five times lower.

SB-HEFA also provides a radically more direct, simpler and more cost-effective route to SAF production than alternative technologies: converting solids directly into liquids without going through a gas phase. Haffner Energy therefore estimates that the CAPEX of an SB-HEFA facility should be approximately one-third that of a solid-biomass-to-liquid-fuels conversion chain based on Fischer-Tropsch or methanol synthesis, while also delivering improved energy efficiency.

Based on its techno-economic model, Haffner Energy is therefore targeting an approximately 50% reduction in the levelised cost of production of renewable diesel and SAF compared with other pathways, including HEFA.

Renewable diesel: SB-HEFA’s first market

Haffner Energy will initially focus the industrial development of SB-HEFA on renewable diesel. Diesel accounts for approximately 34% of refined petroleum products², compared with 9% for kerosene, making it a market nearly four times larger by volume.

Renewable diesel and SAF are two closely related fuels produced through the same conversion chain. Renewable diesel, however, is subject to significantly fewer technical and regulatory constraints than SAF, enabling faster market access.

Unlike conventional biodiesel (FAME), renewable diesel is a hydrocarbon that is chemically very similar to fossil diesel and can therefore be used as a direct substitute.

SB-HEFA aims to bring its cost significantly closer to that of fossil diesel. Its potential markets are substantial, including heavy-duty road transport, agricultural and construction machinery, rail, maritime transport and power generation.

Haffner Energy plans to commission a first complete industrial demonstrator as early as 2027/2028, while non-hydrotreated oil can already be produced today at its Marolles site.

SAF: 2030 is already here

Global SAF production still accounts for only 0.6%³ of kerosene consumption, while its cost is currently two to three times higher⁴. HEFA is by far the leading commercial SAF pathway today, but its development is constrained by the availability and cost of oils and fats. SB-HEFA aims to change this equation by providing access to solid biomass feedstocks that are far more abundant and several times less expensive.

“The main challenge facing SAF today is economics,” said Marcella Franchi, Business Development Director at Haffner Energy. “The key is to overcome the barrier of its high cost while broadening access to sustainable feedstocks that are available at scale. SB-HEFA is specifically designed to address both challenges: to bring the cost of SAF significantly closer to that of fossil kerosene, thereby making the blending targets set by governments and international institutions achievable.”

Haffner Energy intends to initiate the ASTM qualification process for the SB-HEFA pathway to SAF production, drawing in particular on the precedent set by HC-HEFA, the first pathway to benefit from the ASTM D4054 accelerated evaluation process (“Fast Track”) prior to its incorporation into ASTM D7566.

The objective is to enable the commercial deployment of SB-HEFA in aviation from 2030. This timeframe coincides with the increase in the minimum SAF blending mandate in Europe to 6%⁵.

Selling equipment and licences simultaneously

SB-HEFA forms part of Haffner Energy’s technology licensing business model, developed alongside its equipment supply activities, notably illustrated by the CORE100 programme. While CORE100 draws on the Company’s industrial capacity and generates revenue through equipment sales, SB-HEFA will primarily generate licensing revenue without placing significant demands on this capacity. In this context, Haffner Energy is targeting several million euros in upfront fees from the granting of technology licences, supplemented by royalties as well as revenue from services and the supply of strategic components.

In terms of EBITDA contribution, each €1 million in upfront payments or royalties from a licence is equivalent to approximately €3 million in revenue generated through equipment sales. Over the longer term, Haffner Energy also intends to take equity stakes in selected projects, with a view to generating recurring revenue from their operations.

The development of SB-HEFA will be supported by SAF Zero, a dedicated entity focused on developing the SAF business through technology licensing, as well as by Mundi Haffner Technologies, Inc. in Canada. Haffner Energy is also in advanced discussions with an investment bank with a view to appointing it to identify industrial and financial partners that would invest in SAF Zero and finance its development.

The development of SAF Zero is intended to be financed by its partners, without drawing on Haffner Energy’s own financial resources or resulting in any dilution of its shareholders in connection with such financing.

From solid to liquid without going through gas

Producing renewable hydrocarbons from solid biomass is not in itself new. Existing pathways, however, including Fischer-Tropsch, require a complex and highly costly conversion chain involving the production of elementary molecules in gaseous form, which must then be recombined into longer molecules in liquid form.

SB-HEFA oil differs fundamentally from conventional pyrolysis oils, including those produced through fast pyrolysis. The combination of torrefied biomass and the extremely short residence times used in Haffner Energy’s thermolysis process is designed to produce an intermediate that is far better suited to hydrotreatment, notably due to its lower oxygen content and acidity, as well as its very low residual solid particle content.

About Haffner Energy

Haffner Energy designs and supplies innovative solutions for the production of competitive renewable fuels from biomass. With over 33 years’ experience using all types of biomass, the company has developed proprietary thermolysis and gasification technologies enabling the production of renewable gas, hydrogen, renewable methanol, power, and Sustainable Aviation Fuel (SAF).

As well as supplying technology, Haffner Energy supports its clients in developing industrial projects designed to accelerate the decarbonization of the energy, industrial and transport sectors. Its solutions also contribute to the production of biogenic CO₂ and biochar, thereby supporting the energy transition and the sustainable use of biomass.

Haffner Energy is listed on Euronext Growth (ISIN: FR0014007ND6 – Ticker: ALHAF)

Media contact

Laetitia Mailhes
laetitia.mailhes@haffner-energy.com 

+33 (0)6 07 12 96 76

Investor Relations
investisseurs@haffner-energy.com

---

¹ Fastmarkets, Used Cooking Oil (ISCC, DDP Northwest Europe), H1 2026.

² International Energy Agency (IEA), Oil 2017 – Analysis and Forecasts to 2022, “How refiners meet final oil product demand”: diesel 34%; kerosene 9%. Source: IEA – Oil 2017.

³ IATA, Fact Sheet – Sustainable Aviation Fuels, 2025 estimate (SAF ≈ 0.6% of global kerosene consumption).

⁴ World Economic Forum, “The cost of sustainable aviation fuel: Can the industry clear this key hurdle?”, July 2025 (SAF estimated to cost two to three times as much as fossil kerosene through 2030).

⁵ Regulation (EU) 2023/2405 of 18 October 2023 (“ReFuelEU Aviation”), Annex I: minimum SAF share increased to 6% in 2030.

Attachment

• PR_SB HEFA_20260922

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain.

DXS INTERNATIONAL PLC

(AQSE: DXSP)

ANNUAL RESULTS
for the year ended 30 April 2026

The Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2026.

Financial Highlights

• Profit of £61,839 (2025: loss of £94,750).
• Revenue decreased 5.2% to £3,289,052 (2025: £3,469,917).
• Core recurring revenues remained resilient.
• Period-end available cash of £393,258, comprising £83,610 cash at bank and £309,648 of unutilised debtor drawdowns.
• Throughout this period  our strategy has remained to carefully manage costs and cashflow supported by the conversion of accrued management and shareholder loans converted into equity at prices significantly above prevailing market levels.

Commercial Update

Continued investment in customer service and product development has resulted in all customers recently renewing their contracts for a further 18 months. We plan to implement a price increase between April and October 2027, reflecting inflation and expanded product capability. This has the potential to increase annual recurring revenue, although timing and value remain dependent on the new NHS framework.

Balance Sheet and Funding

The Group’s balance sheet strengthened during the year through the conversion of accrued management and shareholder loans into equity at prices significantly above prevailing market levels, minimising dilution to existing shareholders.

NHS Restructuring and Growth

NHS restructuring, which has constrained growth in recent years, is beginning to create meaningful opportunities for DXS. As Integrated Care Boards (ICBs) consolidate, our existing customer base is expected to encompass GP practices representing approximately 6-8 million additional patients who do not currently use DXS SMART Referrals, creating a significant upsell opportunity.

Product Development

SMART Referrals delivered a modest increase in revenue during the year, while our new NexGen SMART Referrals solution has received encouraging feedback from pilot sites. Opportunities within hospital specialist units are also emerging, focused on improving efficiency, reducing administrative workloads and delivering healthcare savings.

ExpertCare, which is aligned with NHS medicines optimisation priorities, is showing encouraging commercial interest, with further traction recorded during the first quarter of 2027.

Pharmaceutical Advertising revenue remained broadly stable, with a modest decline reflecting the timing of medicine information campaigns. It remains an important contributor to DXS revenue.

Outlook

The NHS remains under significant pressure to improve efficiency and patient outcomes, with digital clinical solutions expected to play an increasingly important role in healthcare delivery. This aligns strongly with DXS’ strategy and supports our continued investment in clinical technology, products and services.

David Immelman, Chief Executive of DXS, commented:
“After several challenging years, we believe DXS is increasingly well positioned to benefit from the opportunities emerging across the NHS. Our focus is firmly on converting these opportunities into sustainable recurring revenue growth and improved profitability.

These efforts are underpinned by a talented, dynamic and increasingly experienced team that understands the challenges facing our customers and how DXS can help address them. Alongside our focus on growth, we continue to invest in developing the next generation of leaders within the business, with senior members of the team actively mentoring and supporting their development to ensure continuity, strengthen our capabilities and position DXS for the future.”

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts :

David Immelman, CEO                                                                             Tel: 01252 719800
DXS International plc
www.dxs-systems.com

AQSE Corporate Broker and Corporate Advisor
Hybridan LLP                                                                                            Tel: 020 3764 2341
Claire Louise Noyce

Notes to Editors

About DXS:
DXS International is a UK-based digital health technology company that develops advanced clinical decision support and medicines optimisation solutions widely used across the NHS, particularly in primary care. Its software delivers evidence-based treatment guidelines and recommendations – sourced from Clinical Commissioning Groups and other trusted NHS authorities – directly to doctors, nurses, and pharmacists within their clinical workflow. By enabling better-informed decisions at the point of care, DXS helps improve patient outcomes, enhance safety, and support the NHS in achieving its efficiency and cost-saving objectives

The following information is extracted from the DXS International plc audited accounts for the year ended 30 April 2026.

CHAIRMAN’S REPORT

The year ended 30 April 2026 has been an important period for DXS. While NHS restructuring has delayed purchasing decisions across the UK healthcare sector, this process is creating significant revenue opportunities, explained in more detail below, for DXS. While progress has taken longer than we had hoped, we are now beginning to see tangible developments in several of the areas in which we have invested heavily.

Throughout this period of disruption, our strategy has remained consistent: to continue developing our technology, deliver a high-quality service to our existing customers and carefully manage costs and cashflow. Against this background, the Group returned to profitability during the year.

Financial Highlights

For the year ended 30 April 2026, turnover was £3,289,052 (2025: £3,469,917), with a profit of £61,839 compared with a loss of £94,750 in the prior year. This represents a reduction in turnover of approximately 5.2%, primarily reflecting delayed customer purchasing decisions during NHS restructuring, partially offset by a return to profitability following continued cost discipline. The Group had a reduced Loss from operations and the profit after tax was mainly driven by the R&D Tax credit. Available cash at 30 April 2026 was £393,258 (£83,610 in cash at bank and £309,648 available from the factoring house). The Board continues to monitor the Group’s cash position and working capital requirements closely.

Commercial Update

Our continued investment in customer service and product development has resulted in all of our customers recently renewing their contracts for a further 18 months. We plan to implement a price increase between April and October 2027, reflecting the cost of inflation and expanded product capability. If implemented as planned, we estimate this could significantly increase our annual recurring revenue, although the timing and quantum remain subject to a new NHS framework and are not guaranteed.

Balance Sheet and Funding

The Group’s balance sheet also strengthened during the year, supported by the conversion of accrued management and shareholder loans converted into equity at prices significantly above prevailing market levels; a structure which minimised dilution to existing shareholders. The Board is grateful for this continued support and commitment, which reflects confidence in the Group’s strategy, prospects and long-term potential.

NHS Restructuring and Growth

Importantly, the NHS restructuring that has constrained growth in recent years is now beginning to create meaningful opportunities for DXS. As ICB (Integrated Care Boards) consolidation, from 42 to 28, progresses towards its target, our existing customer base is expected to encompass GP practices representing approximately 6–8 million additional patients that do not currently use our flagship product – DXS SMART Referrals. If only 50% of these customers elected to standardise to DXS SMART Referrals across their practices, this could generate more than £1 million of additional annual recurring revenue. We currently expect the first such upsell opportunities to begin from January 2027, although this depends on the pace of ICB consolidation and on individual ICB customer decision-making, and may occur later.

Product Development

Our existing SMART Referral product showed encouraging results with a modest increase in revenue for the year. ICB customer requested product enhancements continue to be delivered, and our new NexGen SMART Referral solution is receiving enthusiastic feedback from pilot sites.

We are encouraged by progress in developing additional revenue streams. Our Managed Services offering provides clients with an ongoing liaison service with hospital specialist units, helping to ensure that thousands of referral forms remain aligned with their specific requirements and supporting continued reductions in referral rejections.

Our DXS Hubs, Metadata and SMART Forms services provide further opportunities to generate revenue from hospital specialist units and GP practices, while improving efficiency, reducing administrative workloads and delivering savings in both healthcare resources and expenditure.

Fully aligned with NHS priorities for medicines optimisation, our evidenced ExpertCare solution has also been impacted by NHS disruption. There are encouraging signs of commercial interest, and we anticipate further traction during the first quarter of 2027.

Pharmaceutical Advertising revenue remained broadly stable, with a modest decline largely reflecting changes in the timing of medicine information campaigns by advertisers. This remains an important and consistent contributor to DXS’ recurring revenue.

On 18 December 2025, the Board reported that it had suffered a cyber security incident affecting its office servers, which was swiftly contained. DXS has remained vigilant by implementing additional monitoring and security measures.

Outlook

The NHS continues to face significant pressure to improve healthcare efficiency and patient outcomes and is clear in its long-term strategy that digital clinical solutions will play an increasingly important role in healthcare delivery. This direction aligns strongly with DXS’ strategy and validates our continued investment in clinical technology, innovation and the development of our products and services.

After several challenging years, we believe DXS is increasingly well positioned to benefit from the opportunities emerging across the NHS. Our focus is now firmly on converting these opportunities into sustainable recurring revenue growth and improved profitability.

On behalf of the Board, I would like to thank our shareholders, customers and employees for their continued patience, commitment and support.

Bob Sutcliffe

REPORT OF THE DIRECTORS

The directors present their annual report and the audited financial statements for the year ended 30 April 2026. The Chairman’s statement which is included in this report includes a review of the achievements of the Company, the trading performance, financial position, and trading prospects.

DIRECTORS

The directors for the year were:

• Bob Sutcliffe  –  Chairman
• David Immelman  –  CEO
• Steven Bauer  –  COO

PRINCIPAL ACTIVITIES

The Group’s principal activities during the period were the development and distribution of clinical decision support to General Practitioners in the United Kingdom. The commercial side included the licensing of DXS to various ICBs (Integrated Care Boards) and the sale of e-detailing opportunities to the Pharmaceutical Industry.

The Group continues to invest in research and development both locally and internationally and during this financial year has invested £713,472 (2025 – £705,292) excluding the 2026 cost of £595,000 for research and development time spent by the South African subsidiary.

During the period the Group has repaid £61,387 on bank and third-party loans. The company borrowed a further loan of £100,000 with a balance of £89,964 at April 2026.

FINANCIAL INSTRUMENTS

The Directors believe that there is no material risk arising in respect of interest rates on loans, credit, and liquidity.

DIVIDEND

The Directors do not recommend a dividend.

DIRECTORS’ RESPONSIBILITIES

The directors are responsible for preparing the annual report and financial statements for each financial year. The directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the situation of the Group and Company and of the profit or loss of the Group for that period. In preparing these financial statements, the directors are required to:

• Select suitable accounting policies and apply them consistently.
• Make judgments and accounting estimates that are reasonable and prudent.
• State whether UK accounting principles have been followed subject to any material  and explained in the financial statements and,
• Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and Company will continue in the business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company’s transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DIRECTORS’ RESPONSIBILITIES TO AUDITORS

The directors have taken all the necessary steps that they ought to have taken as directors to make themselves aware of all relevant audit information and to establish that the Company’s auditors are aware of that information.

As far as the directors are aware, there is no relevant audit information of which the Company’s auditor is unaware.

Approved by the board and signed on its behalf by:

DA Immelman

10^th September 2026

STRATEGIC REPORT

Section 172 Report

Section 172 of the Companies Act requires that a director of the Company is managing in the best interests of all stakeholders – Customers, Employees and Shareholders. 

In the spirit of above, the Directors of DXS International plc, strive to maintain a reputation for high but fair standards in the best interest of its stakeholders.

Our primary focus is on our customers and here we regard our relationships and channels of communications of paramount importance. We operate in a sensitive environment, healthcare, and as such ensure that we meet all the standards required by our customers, such as Information Governance and Clinical Safety. In addition, we comply with ISO standards which assures an overarching good governance approach to all operations.

The Board is focused on delivering value for Shareholders underpinned by motivated Employees delivering above average delivery of solutions and service to Customers. In achieving the foregoing, the Company focuses on continued innovation via a policy of research and development funded through organic investment plus capital raises, as agreed at shareholder meetings.

In our communication to Shareholders the Board is clear in terms of its short, medium, and long-term strategy and maintains an open-door approach to Shareholders seeking additional clarity on any issue. The Board releases notices on a regular basis informing Shareholders of developments in areas of business progress, non-confidential strategic decisions, and any change to company policy. Risks and opportunities are set out in this strategic review.

The Group is small and while clear management structures are in place all employees, if required, have direct access to the Executive Directors daily and, if necessary, to the Chairman. The Group retains HR services to ensure the fair and equitable treatment of employees. The Company promotes a policy of promoting from within supported by training and mentorship. We encourage diverse thinking and recognise strengths and contribution to the business.

REVIEW OF THE GROUP’S BUSINESS

The Group profit for the year is £61,839 (2025: Loss of £94,750). The 2026 profit is primarily a result of prudent management of costs and an R&D tax credit.

As an accredited NHS solutions provider, DXS has well-established business continuity and disaster recovery protocols in place.

We have continued the development of our new Next-Gen cloud-based system and are in the process of piloting this new version with good results. We are close to completing the Lipids solution and hope to have this commercially viable by Jan 2027.

Although the NHS remains notoriously slow in adopting new technology, our sustained efforts are seeing gained awareness of our new SMART referral and CVD prevention solution which we believe will begin generating revenue in late 2026 or the first quarter in 2027.

Our strategy remains aligned with both the new NHS Long Term Plan and opportunities abroad.

PRINCIPAL RISKS AND UNCERTAINTIES 

The going concern analysis was based on the premise that at worst we will retain existing revenue streams with growth coming only from our new Managed Service offer and a long overdue price increase in October 2027. In an eventuality of neither of these materialising, the company is prepared to implement necessary cost cuts.

The principal risk to the Company in the UK is that the NHS dramatically changes its plans or cuts its budgets. This seems unlikely, particularly with the current NHS’ stated objective for clinicians to operate using digital technologies with which our new Next-Gen and ExpertCare solutions are aligned.

Failure to achieve predicted quantities of DXS contracts, and slower development of additional revenue streams may result in revenues growing more slowly than anticipated. These may be mitigated due to existing DXS customers, with some GP practices not yet having the DXS SMART Referral solution, wanting to standardise with a single referral solution across their complete patch.

ANALYSIS OF BUSINESS DURING YEAR ENDING 30 APRIL 2026

NHS revenue was marginally up with overall revenue down by 5%, mainly due to a small drop in pharma revenue. Results improved with a profit of £61,839 (2025: Loss of £94,750) with available cash of £393,258.

FINANCIAL METRICS

• Group Revenue of £3,289,052 (2025: £3,469,917) has decreased by 5%. Definition: Total Group sales including distribution of clinical decision support to General Practitioners and the licensing of DXS to ICB’s which increased. Group Revenue includes the sale of medicine education slots to the pharmaceutical industry which marginally decreased.
• Underlying Group profit after Tax was £61,839. The profit is mainly a result of prudent management of costs and R&D tax credit.
• Earnings Per Share 2026 0.1p, 2025 (0.1p). Definition: Earnings per share is the underlying profit divided by the weighted average number of ordinary shares in issue.
• ROE 2026 (17%) 2025 (26%). Definition: Return on Equity (ROE) is the ratio of net profit of a company to its shareholders funds. It measures the profitability of a company by expressing its net profit as a percentage of its shareholders funds which include share capital, share premium, provision for costs of share option awards and retained earnings.

CORPORATE GOVERNANCE

We are committed to establish, maintain, and continually improve an Integrated Management System (IMS) that conforms to relevant ISO requirements.

To achieve this objective, we commit to:

• Continual improvement in our performance and services to our stakeholders.
• Identify, assess, reduce, and eliminate hazards and risks pertaining to our business.
• Set risk-based objectives and targets to meet applicable statutory, business, information security

and service level obligations.

• Comply with mutually agreed quality and service level requirements of our customers.
• Develop our people and provide sufficient resources to meet our objectives and targets.

We communicate the IMS Policy to all personnel working for or on behalf of DXS to ensure that they are made aware of their individual IMS obligations.

Approved by the board and signed on its behalf by:

D Immelman

10^th September 2026

FINANCIAL STATEMENTS

INCOME STATEMENT

Year ended 30 April 2026

		2026 Continuing Operations		2025 Continuing Operations
		£		£
Turnover		3,289,052		3,469,917
Cost of Sales		(428,209)		(479,382)
		_________		_________
Gross Profit		2,860,843		2,990,535
Grant income		6,201		132,993
Administration costs		(2,925,528)		(3,251,011)
Depreciation and Amortisation		–		(1,038)
Operating Loss		(58,484)		(128,521)
Sundry income		2,747		1,898
		_________		_________
		(55,737		(126,623)
Interest payable and similar expenses		(40,215)		(48,525)
		_________		_________
Loss on ordinary activities before taxation		(95,952)		(175,148)
Tax on loss on ordinary activities		157,791		80,398
		_________		_________
Profit / (Loss) for the year		61,839		(94,750)
		=========		=========
Earnings per share
basic		0.1p		(0.1p)
fully diluted		0.1p		(0.1p)
		=========		=========

Statement of Other Comprehensive Income

Year ended 30 April 2026		2026 £		2025 £
Profit / (Loss) for the year		61,839		(94,750)
Other comprehensive income		–		–
Tax on components of other comprehensive income		–		–
		_________		_________
Total comprehensive income / (loss) for the year		61,839		(94,750)
		=========		=========

Statement of Financial Position

As at 30 April 2026

	Group 2026	Group 2025	Company 2026	Company 2025
	£	£	£	£
Fixed Assets
Intangible Assets	1,455,000	1,455,000	–	–
Tangible Assets	–	–	–	–
Investments	–	–	744,300	535,768
	_________	_________	_________	_________
	1,455,000	1,455,038	744,300	535,768
	_________	_________	_________	_________
Current assets
Debtors: amounts falling due within one year	524,897	486,556	20,887	44,507
Cash at bank and in hand	83,610	428,957	13,072	16,810
	_________	_________	_________	_________
	608,507	915,513	33,959	61,317
Creditors: amounts falling due within one year	(553,967)	(908,986)	(126,984)	(143,674)
	_________	_________	_________	_________
Net current assets / (liabilities)	54,540	6,527	(93,025)	(82,357)
	_________	_________	_________	_________
Total assets less current liabilities	1,509,540	1,461,527	651,275	453,411
Creditors:
Amounts falling due after more than one year	(243,303)	(285,353)	(164,981)	(95,939)
Deferred income	(779,943)	(814,542)	–	–
	_________	_________	_________	_________
	486,294	361,632	486,294	357,472
	=========	=========	=========	=========
Capital and reserves
Called up share capital	227,857	211,273	227,857	211,273
Share premium	3,314,717	3,213,395	3,314,717	3,213,395
Share option reserve	15,159	15,159	15,159	15,159
Retained earnings	(3,071,439)	(3,078,195)	(3,071,439)	(3,082,355)
	_________	_________	_________	_________
Shareholders’ funds	486,294	361,632	486,294	357,472
	=========	=========	=========	=========

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements. The Company made a profit of £65,999 (2025 – loss of (£98,910) for the year.

The financial statements were approved and authorized for issue by the Board on 10th September 2026.

Signed on behalf of the Board of directors

D Immelman Director

R Sutcliffe Director

Company Registration number :                 06311313

Statement Of Changes in Equity

Year ended 30 April 2026
Group

	Called -up share capital	Share Premium	Share Option Reserve	Retained earnings	Total
	£	£	£	£	£
At 30 April 2024	211,273	3,213,395	11,589	(2,988,871)	447,386
Transfer in respect of expired options	–	–	(5,426)	5,426	–
Cost of share options awarded	–	–	8,996	–	8,996
Loss for the year	–	–	–	(94,750)	(94,750)
	_________	_________	_________	_________	_________
At 30 April 2025	211,273	3,213,395	15,159	(3,078,195)	361,632
Share Issue	16,584	46,239	–	–	62,823
Transfer of reserves	–	55,083	–	(55,083)	–
Profit for the year	–	–	–	61,839	61,839
	_________	_________	________	_________	_________
At 30 April 2026	227,857	3,314,717	15,159	(3,071,439)	486,294
	=========	=========	=========	=========	=========

Transfer from retained earnings to share premium was made in relation to the gain recognised from the waiver of loans to comply with the requirements of UK company law

Company

	Called -up share capital	Share Premium	Share Option Reserve	Retained earnings	Total
	£	£	£	£	£
At 30 April 2024	211,273	3,213,395	11,589	(2,988,871)	447,386
Transfer in respect of expired options	–	–	(5,426)	5,426	–
Cost of share options and warrants awarded	–	–	8,996	–	8,996
Loss for the year	–	–	–	(98,910)	(98,910)
	_________	_________	_________	_________	_________
At 30 April 2025	211,273	3,213,395	15,159	(3,082,355)	357,472
Share Issue	16,584	46,239	–	–	–
Transfer of reserves	–	55,083	–	(55,083)	–
Profit for the year	–	–	–	65,999	65,999
	_________	_________	________	_________	_________
At 30 April 2026	227,857	3,314,717	15,159	(3,071,439)	486,294
	=========	=========	=========	=========	=========

Transfer from retained earnings to share premium was made in relation to the gain recognised from the waiver of loans to comply with the requirements of UK law.

STATEMENT OF CASH FLOWS

Year ended 30 April 2026

		Group 2026		Group 2025
		£		£
Cash flow from operating activities		(476,186)		247,071
Interest paid		(40,215)		(48,525)
Sundry income		2,747		1,898
Loss on Foreign Exchange		(13,097)		–
R&D tax credit received		142,791		195,798
		_________		_________
Net cash flow from operating activities		(383,960)		396,242
		_________		_________
Financing Activities
Repayment of long term loans		(61,387)		(103,431)
Receipt of loan		100,000		–
Advances from directors and senior staff		–		46,134
		_________		_________
		38,613		(57,297)
		_________		_________
Net increase  / (decrease) in cash and cash equivalents		(345,347)		338,945
Cash and Cash equivalents at 30 April 2025		428,957		90,012
		_________		_________
Cash and Cash equivalents at 30 April 2026		83,610		428,957
		=========		=========
Cash and Cash equivalents consists of:
Cash at bank and in hand		83,610		428,957
		=========		=========

Net Debt Reconciliation	Current Debt	Non Current Debt	Cash	Total
	£	£	£	£
At 30 April 2024	(286,629)	(345,455)	90,012	(542,072)
Non – Cash Flow	–	60,102	–	60,102
Cash Flow	209,489	–	338,945	548,434
	________	________	________	________
At 30 April 2025	(77,140)	(285,353)	428,957	66,464
Non – cash flow	–	80,663	–	80,663
Cash Flow		(38,613)	(345,347)	(383,960)
	_________	_________	________	_________
At 30 April 2026	(77,140)	(243,303)	83,610	(236,833)
	=========	=========	=========	=========

NOTES TO THE FINANCIAL STATEMENTS

Year ended 30 April 2026

Summary of significant accounting policies

(a)   General information and basis of preparation.

DXS International PLC is a public company limited by shares incorporated in England and Wales. The address of the registered office is given in the company information on Page 1 of these financial statements.

The group’s principal activities during the year were the development and distribution of clinical decision support to General Practitioners, Nurses and Retail Pharmacies in the United Kingdom. The commercial side includes the licensing of DXS products to various ICB’s (Integrated Care Boards), the sale of e- detailing opportunities to the pharmaceutical industry, the UK Primary Care sector and the licencing of DXS technology to healthcare publishers.

The financial statements have been prepared in accordance with applicable accounting standards including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Companies Act 2006.

The financial statements have been prepared on a going concern basis under the historical cost convention. The financial statements are prepared in sterling which is the functional currency of the company.

In the opinion of the Directors the group has sufficient funding to continue as a going concern for at least twelve months from the date of approval of the financial statements.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

(b )   Intangible assets

Intangible assets acquired separately from a business are capitalised at cost.

Research and development expenditure, other than specific identifiable development expenditure, is written off against profits in the year in which it is incurred.

Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated. Developed products are for use within the NHS and other medical institutions within both the UK and internationally. The Group is already a supplier of services to the NHS.

Intangible assets are amortised over a straight line basis over their useful lives. The useful lives of intangible assets are as follows:

Intangible type	Useful life Reasons	Reasons
Development expenditure	5 years from the date that the specific product is available for distribution	Period of time for benefit to be received.

Provision was made for impairment in 2024 as the recoverable amount of the asset was less than its carrying amount based on Directors judgement of the future revenue to be derived from each product. The Directors have considered the current value of the asset and believe that no additional impairment charge is required in the current year. (Note 1(m))

(c ) Tangible fixed assets

The company capitalises items purchased as Tangible Fixed Assets which have a cost in excess of £550.

Tangible fixed assets are stated at cost less accumulated depreciation.

Depreciation is provided on all tangible fixed assets at rates calculated to write off the cost , less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Office equipment

3-4 years straight line.

(d)   Debtors and creditors receivable/ payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administration expenses.

(e)   Loans and borrowings

Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently they are measured at amortised cost using an effective interest rate method. If an arrangement constitutes a finance transaction it is measured at present value.

(f)   Grants

Government Grants, including non – monetary grants, shall not be recognised until there is reasonable assurance that :

      (a)   the entity will comply with the conditions attached to them; and

      (b)   the grants will be received.

An entity shall recognise grants either based on the performance model or the accrual model. In the current year and prior year, the Grant has been accounted for on the accrual basis over the period in which the Group recognised the related costs for which the grant is intended to compensate.

(g)   Tax

Current tax represents the amount of tax payable or receivable in respect of the taxable profit for the current or past reporting periods. It is measured at the amount expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted by the reporting date.

(h)   Turnover and other income

Turnover is measured at the fair value of the consideration received or receivable net of VAT and trade discounts. The policy adopted for the recognition of turnover is as follows:

Sale of services and products

Turnover is from the sale of products and services to the pharmaceutical industry and the UK Primary Care sector and is recognised over the term of service contract and is apportioned on a time basis representing the delivery of the service.

(i)   Foreign currency

Foreign currency transactions are initially recognised by applying to the foreign currency amount the exchange rate between the functional currency and the foreign currency at the date of the transaction.

Monetary assets and liabilities denominated in a foreign currency at the balance sheet date are translated using the closing rate.

Foreign exchange gains or losses are recognised in the Income Statement.

(j)   Employee benefits

When employees have rendered service to the company, short term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The company operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

(k)   Leases

Rentals payable under operating leases are charged to the income statement on a straight line basis over the period of the lease.

(l) Share option policy

The company recognised as an expense, the fair value of share options granted over their vesting period. The fair value is calculated by applying an option pricing model.

(m)   Key judgements and Key accounting estimates

The Key judgements or Key Accounting estimates with a material effect on the carrying value of assets and liabilities are set out below -.

Going concern

In regards to the going concern of the group, the directors have considered cash flow forecasts for the period to April 2028 which include estimates to be earned from the new Next Gen SMART Referral solution which is anticipated to be available for distribution during early 2027. Indications are that there will be a significant demand for this product. Existing Point of Care customers have all renewed their continuity contracts until September 2027. Also included within the Budget is a CPI price increase in April 2027 and a long overdue product price increase in October 2027. The renewal of the NHS central funding framework which is expected to become effective in October 2027 will enable existing NHS customers to procure the DXS SMART Referral solution for practices that as yet do not have the referral solution

The Expertcare solution has been selected, provisionally, for inclusion in a major project by the NHS commencing in early 2027.

The successful evaluations of both the SMART Referral and Expertcare solutions, both demonstrating strong ROI for the NHS, bode well for procuring new sales for these solutions for 2027/28.

The Pharma division has found a number of new customers since the year end. A price increase has also been implemented in the current year, which has been accepted by the current customers. The indication is that, with the benefit of the new products, this division will be expanding in the forthcoming year.

Also included are costs which, if forecasted sales are slower than anticipated, can be reduced accordingly. While the forecasts include a number of positive assumptions relating to new customer acquisitions, anticipated sales from recently developed products, future contract opportunities, planned price increases and potential cost mitigation actions, these represent managements best estimates rather than assumptions fundamental to the going concern assessment. Sensitivity analysis performed demonstrates that, even if these forecast benefits are excluded in full, the Group continues to maintain adequate liquidity and headroom throughout the forecast period and remains able to meet its liabilities as they fall due. Accordingly, the directors’ conclusion that the Group is a going concern is not dependent upon the successful delivery of these initiatives, and no material uncertainty relating to going concern has been identified.

Based on the foregoing, the directors consider it appropriate to adopt the going concern basis of accounting and are satisfied that there is no material uncertainty.

Research and Development Tax credit

The Research and Development tax credit received from HMRC is not a Government grant but a recognition of the costs incurred in respect of the company’s research and development and is received through an adjustment to the taxable income of the company.

Impairment

As per the NHS mandate requiring NHS accredited suppliers to continue a process of innovation, the Group has invested heavily into developing new innovative solutions to meet the NHS unmet needs. However, while there is no doubt as to the potential benefits to be realised for the NHS, the slow pace at which the NHS has been, and continues to operate is frustrating.

The Government did not provide the anticipated funding to the NHS during 2024/25 or 2025/26 . Funds were not available for purchase of new products by the NHS, The Government has indicated that significant funds for new products will be made available in the fiscal year commencing October 2027.

The slow pace at which the NHS has operated over the last few years has been extremely frustrating. The main reasons are the reduction in the ICBs causing staff concerns for potential staff redundancies, the delayed appointment of senior staff in the new combined organisations and the appointment of 2 Secretaries for State since the last General election.

There are indications that the NHS is slowly improving its delivery time for patients and is taking steps to resolve the current issues within product procurement.

The company’s products are in line with the those included in the NHS new 10 year plan. The new products are undergoing pilot testings. The initial reports indicate that only minor amendments to the products are required. And there appears a demand for these products when they have completed all the tests. There are also studies showing a significant cash saving to the NHS by the utilisation of these products

Given all these factors, the Directors believe that there are no impairment indicators and no further impairment provision is required in the current year.

(n)   Reduced disclosure

DXS International PLC meets the definition of a qualifying entity under FRS 102 paragraph 1.12(b) and has therefore taken advantage of the disclosure exemption in relation to the parent cash flow statement.

Attachment

• DXS – Announcement Full Year 2026 – 22 September 2026